drugset
drugset / Trial / NCT02488629

Study of SCB01A in Patient With Head and Neck Cancer

NCT02488629 ↗

Phase 2 Terminated 5 enrolled SynCore Biotechnology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of SCB01A in head and neck cancer.

Timeline

Start
2015-09
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SCB01A Unknown — —

Indications

head and neck squamous cell carcinoma